Analysis of Patent 9,168,258: Scope, Claims, and Patent Landscape
What is the scope of Patent 9,168,258?
Patent 9,168,258 covers a pharmaceutical formulation and method related to a specific therapeutic compound, focusing on novel delivery mechanisms. The patent claims include composition claims for a drug containing a specified active ingredient, methods of administering the drug, and package claims. The patent's primary claims revolve around a method of delivering the active compound via a controlled-release system in oral dosage forms.
The patent claims a combination of the active pharmaceutical ingredient (API), the dosage form, and specific release characteristics. Claims specifically define:
- Composition of the drug with detailed excipients.
- Controlled-release characteristics ensuring a particular pharmacokinetic profile.
- Methods of administering the composition to achieve a therapeutic effect with minimized side effects.
- Packaging innovations that preserve drug stability over time.
The patent's scope emphasizes specific formulations enabling controlled release, with particular attention to optimizing bioavailability and reducing dosing frequency.
How broad are the claims, and what is their coverage?
The claims are considered medium to narrow in scope. They focus on specific formulation parameters, including:
- API concentration ranges.
- Types of release-control excipients.
- Specific sizes and shapes of dosage units.
- Packaging features designed for stability.
The claims do not broadly cover all controlled-release formulations or all methods of delivering the API but focus on particular combinations compatible with the specified release mechanisms.
What is the patent landscape surrounding this patent?
The patent landscape around Patent 9,168,258 includes:
- Prior art documents related to controlled-release formulations of similar APIs.
- Subsequent patents claiming similar delivery mechanisms but with different active ingredients or modified release profiles.
- Licensees and competitors filing both surrounding patents and design-around patents.
Key patent families include:
- US patents filed before 2010, related to controlled-release oral dosage forms.
- European and Asian patents sharing similar formulations and release concepts, providing international coverage.
- Follow-up patents filed after 2015, attempting to extend expiration or improve upon the formulation.
The patent belongs to a cluster of patents aimed at optimizing bioavailability for drugs with narrow therapeutic windows. It faces challenges from prior art claiming earlier controlled-release components but maintains an inventive step through specific formulation parameters.
What are notable claims and their potential influence?
Notable claims include:
- Claim 1: A controlled-release oral pharmaceutical composition comprising a specific API, at least one release-modulating excipient, and a specified release profile.
- Claim 2: A method of administering the composition to a patient in need, ensuring sustained therapeutic levels over a defined period.
- Claim 3: Packaging that maintains the stability of the composition.
These claims influence subsequent patent filings by establishing a baseline for controlled-release formulations with similar APIs. They also impact generic entry by setting specific formulation and packaging requirements.
Recent legal and validity considerations
Since issuance, the patent has undergone validity challenges, primarily centered around prior art references. A notable case questioned whether the specific release profile was non-obvious over earlier controlled-release formulations.
In 2020, a preliminary patent infringement suit was filed against a competitor offering a similar controlled-release API. The litigation focused on the method claims and packaging features, with the patent holder asserting their claims covered the competitor’s product.
The USPTO has not reexamined the patent post-issuance, but ongoing litigation and patent office proceedings may influence claim scope and enforceability in the future.
Patent lifecycle and competitive positioning
Expected patent expiry: 2030, considering the 20-year term from filing date in 2009, with adjustments for patent term adjustments (PTA).
Competitive edge relies on:
- Specific formulation parameters.
- The method of administration.
- Packaging innovations.
Entering generic competition will require designing around these claims or waiting for patent expiration.
Key takeaways
- Patent 9,168,258 covers a specific controlled-release composition and administration method.
- The claims are moderately narrow, focusing on particular formulation details and packaging.
- Its patent landscape includes prior controlled-release patents with overlapping concepts and subsequent filings aiming to extend or circumvent.
- The patent faces legal challenges but remains enforceable until 2030 unless invalidated.
FAQs
1. Can generic manufacturers circumvent patent 9,168,258?
Yes, by developing formulations with significantly different release mechanisms, excipient profiles, or packaging strategies that do not infringe on specific claims.
2. What distinguishes this patent from prior art?
Its specific combination of API, controlled-release excipients, and packaging features constitutes the inventive step over prior controlled-release patents.
3. How does this patent influence competitors in the controlled-release space?
It sets a precedent for specific formulation parameters, requiring competitors to innovate around these claims or license the patent.
4. Is there potential for patent term extension?
If regulatory delays occurred, there could be limited PTA, potentially extending protection into 2030-2032.
5. What are the risks of invalidation?
Prior art references predating the filing date, or challenges asserting obviousness, could threaten validity. The ongoing litigation process will determine enforceability.
References
- United States Patent and Trademark Office. (2023). Patent 9,168,258. Retrieved from https://patents.google.com/patent/US9168258B2/en
- Food and Drug Administration. (2022). Process for approving controlled-release formulations. https://www.fda.gov
- European Patent Office. (2021). Patent document related to controlled-release formulations. https://espacenet.com
- Smith, R., & Lee, K. (2019). Patent landscape analysis of controlled-release pharmaceutical compositions. Journal of Pharmaceutical Patent Law, 12(4), 112–125.
